Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
Patents for C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
12/2008
12/04/2008US20080300261 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease
12/04/2008US20080300260 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor)
12/04/2008US20080300240 Pde10 inhibitors and related compositions and methods
12/04/2008US20080300232 N-Piperidine Derivatives as Ccr3 Modulators
12/04/2008US20080299089 Endogeneous repair factor production promoters
12/04/2008CA2687933A1 Method for the electrochemical detection of nucleic acid sequences
12/04/2008CA2686651A1 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
12/03/2008EP1997823A1 Boronic ester and acid compounds, synthesis and uses
12/03/2008EP1997806A1 Pahrmaceutical compositions for prevention and treatment of central nervous system disorders
12/03/2008EP1997800A1 N-2-(hetero)arylethylcarboxamide derivative, and pest-controlling agent comprising the same
12/03/2008EP1786776B1 Method for producing high-purity quaternary ammonium compounds
12/03/2008EP1575921B1 Process for the synthesis of isonicotinic acid hydrazide
12/03/2008EP1492785B1 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
12/03/2008EP1377540B1 Inhibitors of integrin alpha-v-beta-6
12/03/2008EP0900200B1 Pharmaceutical compositions for prevention and treatment of central nervous system disorders
12/03/2008CN101316820A Process for preparation of chiral amlodipine gentisate
12/03/2008CN101314589A Preparation for 2,6-diamino-3, 5-di nitryl pyridine
12/03/2008CN101314588A Preparation for 6-chlorine-2-trichloromethyl pyridine
12/03/2008CN100439379C Method for producing highly pure tris-ortho metalated organoiridium compounds
12/03/2008CN100439368C Organic eurepium compound based on functional o-phenan throline ligand and its electroluminous device
12/03/2008CN100439357C Benzo [b][1,4] dioxepine derivatives
12/03/2008CN100439339C 2-pyridone derivatives as netrophil elastase inhibitors and their use.
12/03/2008CN100439332C Novel thiourea derivatives and the pharmaceutical compositions containing thd same
12/03/2008CN100439323C Production of secondary-amine compound
12/03/2008CN100438910C Preventives/remedies for liver diseases
12/03/2008CN100438865C Compounds having fungicidal activity and processes to make and use same
12/02/2008US7459585 Benzene derivatives and pharmaceutical use thereof
12/02/2008US7459580 Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives
12/02/2008US7459563 Process for the preparation of isonicotinic acid derivatives
12/02/2008US7459562 Monocyclic heterocycles as kinase inhibitors
12/02/2008US7459479 Benzylated PDE4 inhibitors
12/02/2008US7459477 Chemical intermediate for agriculture, horticulture compounds; insecticide, fungicides, miticides
12/02/2008US7459470 For example, N-(Isoquinolin-3-yl)-2-(4-pyridylmethyl)aminobenzoic acid amide-N-oxide; use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, such as psoriasis, arthritis, hemangioma, angiofibroma, eye diseases, cirrhosis of the liver
12/02/2008US7459469 N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders
12/02/2008US7459468 3-{4-Hydroxymethyl-5[(2'-sulfamoyl-biphenyl-4-ylamino-methyl]-pyridin-3-yloxymethyl}-benzamidine; protease inhibitors of blood; block platelet aggregation; cardiovascular diseases like angioplasty, hypertrophy, congestive heart failure, arrhythmia, ischemia reperfusion injury; coating on a medical device
12/02/2008US7459467 selective and complete reduction of pyridine ring in a biaryl system comprising proportional-variant -substituted or non-substituted benzene ring; Attention Deficit Hyperactive Disorder (ADHD) and central nervous system stimulant
12/02/2008US7459460 Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
12/02/2008CA2377668C Novel naphthylsulfonic acids and related compounds as glucose uptake agonists
12/02/2008CA2344144C Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
12/02/2008CA2305548C Prostaglandin agonists and their use to treat bone disorders
12/02/2008CA2186380C Novel carbamates and ureas as modifiers of multi-drug resistance
12/02/2008CA2182062C Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents, and medicaments comprising them
11/2008
11/27/2008WO2008144045A1 Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
11/27/2008WO2008143324A1 Organic-inorganic hybrid polymer, method for production thereof, and method for control of molecular weight
11/27/2008WO2008142542A2 Processes for preparing benzofuro [3, 2-c] pyridine- 9-carbaldehyde derivatives as novel intermediates for the synthesis of pde iv inhibitors
11/27/2008WO2008142454A1 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
11/27/2008WO2008142106A1 Salts of picotamide
11/27/2008WO2008092072A3 Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
11/27/2008WO2008030838A3 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity
11/27/2008WO2008013963A3 Fatty acid amide hydrolase inhibitors
11/27/2008US20080294289 Preparation and Use of Alkylating Agents
11/27/2008US20080293741 Tricyclo Substituted Amides as Glucokinase Modulators
11/27/2008US20080293727 Amine hydroxyalkyl sulfonamides as enzyme inhibitors; for example, N-1-(3-((3-acetylamino-4-fluoro-benzenesulfonyl)-benzyl-amino)-(1S,2 syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide; may be used as anti-viral agents against the HIV-1 and HIV-2 viruses
11/27/2008US20080293722 Ion Channel Modulators
11/27/2008US20080293720 Pyridinyl Sulfonamide Modulators of Chemokine Receptors
11/27/2008US20080293717 Aryl sulfonamides
11/27/2008US20080293687 Benzamide Compounds
11/27/2008US20080293684 Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors
11/27/2008US20080293680 Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
11/27/2008US20080293678 Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use
11/27/2008US20080293137 Compounds that abrogate dna damage induced cell cycle g2 checkpoint and/or augment anti-cancer activity of dna-damaging treatments
11/27/2008US20080289124 Reactive Azo Dyes, Methods for the Production Thereof and Their Use
11/27/2008DE102007023747A1 Organisches elektrochromes Bauelement für Daueranzeigen Organic electrochromic device for continuous displays
11/26/2008EP1995322A1 Method for purification of amino acid
11/26/2008EP1994029A2 Potassium channel inhibitors
11/26/2008EP1994004A2 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
11/26/2008EP1994001A2 Benzeneszkfibate salts and their use as intermediates for the synthesis of 2-[2-(1-alkyl-2-piperidyl)ethyl] cinnamanilides
11/26/2008EP1993551A2 Potassium channel inhibitors
11/26/2008EP1603877B1 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS
11/26/2008EP1506162B1 Synthesis of benzonitriles and benzimidates
11/26/2008CN101312975A Method for 1h-imidazo[4,5-c]pyridines and analogs thereof
11/26/2008CN101312719A Novel phloroglucinol derivatives having selectin ligand activity
11/26/2008CN101311174A Vitamin B6 derivates and pharmaceutical use thereof
11/26/2008CN100438123C Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such
11/26/2008CN100436648C Method and apparatus for electrolytic synthesis of 3,6-dichloropyridine-carboxylic acid
11/26/2008CN100436450C Novel triarylimidazoles
11/26/2008CN100436447C Compounds possessing neuronal activity
11/26/2008CN100436425C Fused imidazolium derivatives
11/26/2008CN100436419C Alkali metal salt of 6-substituted amino-3,5-dihalogeno-2-pyridol and its prepn and application
11/26/2008CN100436418C N-Benzyl-3-indenylacetamides derivatives for treating neoplasia
11/26/2008CN100436415C Process for the preparation of (R)-& alpha, -(2,3-dimethoxyp-henyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
11/25/2008US7456315 Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
11/25/2008US7456302 Method for producing pentacyclic taxans
11/25/2008US7456291 Use of a vitamin combination for the treatment of primary headaches
11/25/2008US7456290 Process for the preparation of 2-aminomethylpyridine derivative
11/25/2008US7456285 Use of metal complex compounds as oxidation catalysts
11/25/2008US7456218 3-(4-{[4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2-fluorophenyl)propanoic acid; superior GPR40 receptor function modulating action, can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes
11/25/2008US7456196 Alzheimer's disease; antihistamine; attention deficit disorder; hyperactivity; bipolar disorder; cognition activators; psychological disorder; anticancer agent; antidepressants; antiepileptic agents; gastrointestinal disorder; analgesics; 6-{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-2-(3-pyridinyl)quinoline
11/25/2008US7456175 For treatment and/or prevention of diseases which are associated with the modulation of H3 receptors; treatment of obesity; N-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-propionamide, 1-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-3-propyl-urea
11/25/2008US7455827 Process for preparing a catalyst for conversion of cyanopyridines to nicotinamides
11/25/2008CA2260469C A process for the preparation of pyridine dicarboxylate derivatives
11/20/2008WO2008140338A1 New ionic pairs with (4-chloro-2-methylphenoxy)acetate and their syntheses
11/20/2008WO2008140066A2 Pyridone derivatives as p38a mapk inhibitors
11/20/2008WO2008139987A1 G-protein-conjugated receptor agonist
11/20/2008WO2008139879A1 G protein-coupled receptor inhibitor and pharmaceutical product
11/20/2008WO2008138812A2 Pyridinone based azo dyes and their metal complex salts
11/20/2008WO2008138594A1 Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
11/20/2008WO2008109697A3 Ppar active compounds
11/20/2008US20080287674 Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade
11/20/2008US20080287522 reduced or no emetogenic effects ; benzylated phosphodiesterase 4 inhibitors; e.g. Rolipram, Ariflo, Arofylline; preparation by benzylation using benzyl bromide or a derivative; antiinflammatory agents; to treat autoimmune diseases; cystic fibrosis
1 ... 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 ... 633